7-氟-5-溴-1,2,3,4-四氢乙酯 | 393509-21-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 中文名称: 7-氟-5-溴-1,2,3,4-四氢乙酯
• 英文名称: ethyl (7-fluoro-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetate
• 英文别名: (+/-)-(7-fluoro-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid ethyl ester；(7-Fluoro-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid ethyl ester；Ethyl 2-(7-fluoro-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetate
• CAS: 393509-21-2
• 化学式: C₁₅H₁₆FNO₂
• 分子量: 261.296
• InChiKey: DUDTZVCHBINVOE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  19
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  42.1
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  7-氟-5-溴-1,2,3,4-四氢乙酯 在 吡啶 、 盐酸 、 sodium hydroxide 、 copper(l) iodide 、 (S)-(-)-1-(1-naphthyl)ethylamine salt 、 sodium hydride 、 溶剂黄146 、 pyridinium hydrobromide perbromide 、 锌 作用下， 以 四氢呋喃 、 N-甲基吡咯烷酮 、 甲醇 、 乙醚 、 N,N-二甲基甲酰胺 为溶剂， 反应 9.0h， 生成 拉罗皮兰
  参考文献：
  名称：

  Discovery of a Potent and Selective Prostaglandin D₂ Receptor Antagonist, [(3R)-4-(4-Chloro- benzyl)-7-fluoro-5-(methylsulfonyl)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl]-acetic Acid (MK-0524)

  摘要：

  The discovery of the potent and selective prostaglandin D-2 (PGD(2)) receptor (DP) antagonist [(3R)-4-(4-chlorobenzyl)-7-fluoro-5-(methylsulfonyl)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl]-acetic acid (13)is presented. Initial lead antagonists 6and 7were found to be potent and selective DP antagonists (DP K-i = 2.0 nM for each); however, they both suffered from poor pharmacokinetic profiles, short half-lives and high clearance rates in rats. Rat bile duct cannulation studies revealed that high concentrations of parent drug were present in the biliary fluid (C-max = 1100 mu M for 6and 3900 mu M for 7). This pharmacokinetic liability was circumvented by replacing the 7-methylsulfone substituent present in 6and 7with a fluorine atom resulting in antagonists with diminished propensity for biliary excretion and with superior pharmacokinetic profiles. Further optimization led to the discovery of the potent and selective DP antagonist 13.

  DOI：

  10.1021/jm0603668
• 作为产物：
  描述：

  4-氟苯胺 在 palladium diacetate 硅酸四乙酯 、 碘 、 4-甲基苯磺酸吡啶 、 碳酸氢钠 、 N,N-二异丙基乙胺 作用下， 以 水 、 N,N-二甲基甲酰胺 、 甲苯 为溶剂， 反应 8.5h， 生成 7-氟-5-溴-1,2,3,4-四氢乙酯
  参考文献：
  名称：

  Discovery of a Potent and Selective Prostaglandin D₂ Receptor Antagonist, [(3R)-4-(4-Chloro- benzyl)-7-fluoro-5-(methylsulfonyl)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl]-acetic Acid (MK-0524)

  摘要：

  The discovery of the potent and selective prostaglandin D-2 (PGD(2)) receptor (DP) antagonist [(3R)-4-(4-chlorobenzyl)-7-fluoro-5-(methylsulfonyl)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl]-acetic acid (13)is presented. Initial lead antagonists 6and 7were found to be potent and selective DP antagonists (DP K-i = 2.0 nM for each); however, they both suffered from poor pharmacokinetic profiles, short half-lives and high clearance rates in rats. Rat bile duct cannulation studies revealed that high concentrations of parent drug were present in the biliary fluid (C-max = 1100 mu M for 6and 3900 mu M for 7). This pharmacokinetic liability was circumvented by replacing the 7-methylsulfone substituent present in 6and 7with a fluorine atom resulting in antagonists with diminished propensity for biliary excretion and with superior pharmacokinetic profiles. Further optimization led to the discovery of the potent and selective DP antagonist 13.

  DOI：

  10.1021/jm0603668

文献信息

• Method of Treating Pathological Blushing
  申请人：Tobert A. Jonathan

  公开号：US20070299122A1

  公开（公告）日：2007-12-27

  A method of treating pathological blushing is disclosed wherein the patient is administered a DP receptor antagonist. Compositions containing DP antagonists are also included.

  揭示了一种治疗病理性面红的方法，其中患者接受DP受体拮抗剂。还包括含有DP拮抗剂的组合物。
• Method of treating atherosclerosis, dyslipidemias and related conditions
  申请人：——

  公开号：US20040229844A1

  公开（公告）日：2004-11-18

  A method of treating atherosclerosis is disclosed wherein nicotinic acid or another nicotinic acid receptor agonist is administered to the patient in combination with a DP receptor antagonist. The DP receptor antagonist is administered to reduce, prevent or eliminate flushing that may otherwise occur.

  揭示了一种治疗动脉粥样硬化的方法，其中尼古酸或其他尼古酸受体激动剂与DP受体拮抗剂联合给患者使用。DP受体拮抗剂被用来减少、预防或消除可能发生的潮红。
• [EN] FLUORO-METHANESULFONYL-SUBSTITUTED CYCLOALKANOINDOLES AND THEIR USE AS PROSTAGLANDIN D2 ANTAGONISTS<br/>[FR] FLUORO-METHANESULFONYL- CYCLOALKANOINDOLES SUBSTITUES ET LEUR UTILISATION EN TANT QU'ANTAGONISTES DE PROSTAGLANDINE D2
  申请人：MERCK FROSST CANADA INC

  公开号：WO2004103970A1

  公开（公告）日：2004-12-02

  Novel cycloalkanoindole derivatives of formula (I) are antagonists of prostaglandins, and as such are useful for the treatment of prostaglandin mediated diseases.

  化合物(I)的新型环烷基吲哚衍生物是前列腺素拮抗剂，因此对于治疗前列腺素介导的疾病是有用的。
• Fluoro substituted cycloalkanoindoles, compositions containing such compounds and methods of treatment
  申请人：——

  公开号：US20030158246A1

  公开（公告）日：2003-08-21

  Fluoro substituted cycloalkanoindole derivatives are antagonists of prostaglandins, and as such are useful for the treatment of prostaglandin mediated diseases.

  氟代环烷基吲哚衍生物是前列腺素拮抗剂，因此可用于治疗前列腺素介导的疾病。
• Asymmetric Synthesis of a Prostaglandin D₂ Receptor Antagonist
  作者：Kevin R. Campos、Michel Journet、Sandra Lee、Edward J. J. Grabowski、Richard D. Tillyer

  DOI：10.1021/jo048305+

  日期：2005.1.1

  An asymmetric synthesis was developed for the production of a prostaglandin D2 receptor antagonist for the treatment of allergic rhinitis. The stereogenic center was set using asymmetric allylic alkylation chemistry, and the core of the structure was constructed via Pd-catalyzed N-cyclization/Heck methodology. The synthesis relies on a late stage indoline oxidation which does not racemize the product

  开发了一种不对称合成物，用于生产前列腺素D 2受体拮抗剂，用于治疗变应性鼻炎。使用不对称烯丙基烷基化化学方法设定立体异构中心，并通过Pd催化的N-环化/ Heck方法构建结构的核心。合成依赖于后期的二氢吲哚氧化，不会使产物外消旋。